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ABSTRACT
Purpose: This cross-sectional study compared macular pigment (MP) levels among persons with Type 2
diabetes relative to healthy controls. Additionally, a range of behavioral, anthropometric, clinical and
serum measures were explored as possible predictors of low MP optical density (MPOD) in diabetes.
Methods: Two health status groups; Group 1: Type 2 diabetes (n = 188), and Group 2: Healthy controls
(n = 2,594) completed a full MP assessment using customized heterochromatic flicker photometry, as
part of The Irish Longitudinal Study on Aging (TILDA). Clinical [blood pressure; cataract status; MPOD]
and anthropometric [waist (cm); weight (kg); hip (cm)] measurements were taken, and a blood sample
drawn for analysis of serum biomarkers [lipoproteins; inflammatory markers (C reactive protein and
vitamin-D)].
Results: One-way ANOVA revealed lower MPOD in subjects with Type 2 diabetes relative to controls
(p = .047). Amongst participants with diabetes, those with low serum vitamin D (≤50 nmol/L) had
significantly lower mean MPOD compared to those with sufficient serum vitamin D levels >50 nmol/L
(0.173(0.148) vs. 0.226(0.145); p = .006). Concomitantly, MP was significantly lower in diabetes partici-
pants with raised serum triglyceride (TG) to high density lipoprotein (HDL) ratio (TG/HDL); values
>1.74 mmol/L (0.172 (0.140) vs 0.215 (0.152); p = .039). Body mass index, waist-to-height ratio and
waist circumference, were all significantly negatively correlated with MPOD (Pearson’s correlation,
p < .05 for all). Significant correlates of MPOD in the multivariate regression model included smoking,
cataract, and vitamin D, which collectively contributed 18.5% of the overall variability in MPOD status
amongst participants with Type 2 diabetes.
Conclusions: This study provides additional evidence that low MP may indeed be a feature of Type 2
diabetes, and further identifies smoking, cataract and vitamin D status as plausible predictors of low
MPOD amongst persons with Type 2 diabetes.
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Introduction
The prevalence of diabetes has been increasing steadily
over recent decades and is now reaching epidemic
proportions.1 Type 1 and Type 2 diabetes are the two
main forms of diabetes, however, Type 2 diabetes is
much more common and is estimated to affect more
than 500 million people worldwide.2 Diabetic retinopathy
(DR), a debilitating microvascular complication of dia-
betes, is the most common cause of vision loss in people
with diabetes and is a leading global cause of vision
impairment and blindness among working-age adults.3
The pathogenesis of DR is multifactorial and remains
poorly understood. Chronic hyperglycemia induces oxidative
stress in the retina4, and it is thought that hyperglycaemia
causes tissue damage through a number of major pathways,
including the polyol pathway, activation of protein kinase
C (PKC), upregulation of advanced glycation end product
formation and activity of the hexosamine pathway.5
Interaction of these biochemical pathways may cause
a cascade of events, such as apoptosis, oxidative stress, inflam-
mation and angiogenesis, which can lead to damage of the
diabetic retina, as reviewed by Al-Kharashi.6 It is thought that
hyperglycemia leads to a dysregulation of inflammation,
which in turn leads to an increase in the level of pro-
inflammatory proteins.7 Inflammatory processes underlie
many of the functional retinal vasculature alterations observed
histologically in early DR.8 Animal and human studies have
confirmed that all retinal cell types, including inner retinal
neurons, Muller cells and astrocytes, are damaged by
diabetes.9 Recognizing both the clinical and histological
aspects of retinal change in diabetic macular edema and DR
is essential to understanding the mechanisms of vision loss in
diabetes, and in developing early-stage clinical interventions
that effectively target the specific etiologies and underlying
pathological mechanisms of the condition. In fact, insulin
resistance, impaired glucose tolerance and Type 2 diabetes
may exist for many years before clinical retinal signs become
evident.10
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The body’s natural defence against oxidative damage and
inflammation is the neutralization of reactive oxygen species
(ROS) with endogenous antioxidants, both enzymatic and non-
enzymatic.11 These endogenous antioxidants work with exogen-
ous antioxidants (vitamin C, vitamin E and carotenoids such as
beta carotene, lutein, zeaxanthin andmeso-zeaxanthin),12 together
balancing redox status. The carotenoids, lutein, zeaxanthin and
meso-zeaxanthin, collectively known in the eye as macular pig-
ment (MP); confer potent anti-oxidant and anti-inflammatory
effects at the macula.13,14 These carotenoids are uniquely concen-
trated in the inner and central layers of the primate macula, and
while there have been numerous studies looking at the role of
carotenoids and other nutrients in the prevention of AMD,
reviewed elsewhere,15 the association between diabetes and
MPOD levels, however, has received somewhat less attention.
The evidence that does exist, however, suggests that the
relationship is worth exploring in more detail. Serum concen-
trations of lutein and zeaxanthin have been observed to be
significantly lower in patients with DR.16 Furthermore, MP
has been found to be significantly lower in patients with
diabetes,17 with one study reporting lower levels of MP in
Type 2 versus Type 1 patients.18 It is also possible that MP
may confer therapeutic benefits in diabetic eye disease.
A number of studies have explored the effect of MP supple-
mentation in diabetes. Although the evidence is far from
definitive, improvements in structural and functional mea-
sures of ocular health in response to macular carotenoid
supplementation have been found. The earliest of these stu-
dies reported improvements in vision and macular edema
following supplementation.16 The diabetes visual function
supplement study (DiVFuSS) suggested that a nutritional sup-
plement containing lutein and zeaxanthin mitigated the
damaging effects of systemic inflammation on ocular func-
tion, and that these beneficial effects may have been mediated
by enhancements in MPOD.19 Improvements in visual func-
tion have also been observed in patients with diabetes follow-
ing supplementation, including in contrast sensitivity20 and in
electrophysiological indices of retinal function.21
The reasons why MPOD levels might be adversely affected in
diabetes are yet to be elucidated, but a number of factors might be
important. At presentation, Type 2 diabetes is most often accom-
panied by other co-morbidities including overweight/obesity,
insulin resistance, hypertension and dyslipidemia,22 which may
adversely affect MP by compromising the availability,23
transport,24 assimilation24 and maintenance/retention of dietary
carotenoids in the retina. De novo synthesis of carotenoids is not
possible in humans, therefore, the chronic low-grade
inflammation7 and pro-oxidative environment4 associated with
Type 2 diabetes may negatively impact MPOD levels in the eye.
Macular pigment levels can be measured in vivo, but are
not routinely measured in clinical practice. Given the possi-
bility that higher levels of MP may be beneficial for vision and
ocular health in diabetes, the investigation of surrogate indi-
cators of MP status that are more readily and routinely mea-
sured is merited. The capacity of such an alternate biomarker
to expedite the identification and treatment of patients at risk
of low MP could be particularly important given that retinal
damage can occur long before visual signs of DR are evident.
This study was designed, therefore, to compare MPOD in
participants with and without Type 2 diabetes and, more
importantly, to explore a range of behavioral, anthropometric,
clinical and serum biomarkers as possible predictors of risk
for low MPOD among individuals with Type 2 diabetes.
Methods
Study population
The Irish Longitudinal Study on Ageing (TILDA) is
a large prospective cohort study examining the social,
economic and health factors which influence healthy age-
ing in older adults resident in Ireland.25 Cross-sectional
data from TILDA was analyzed in this study. A stratified
clustered sample of 8,175 individuals, representative of
the population of Ireland, aged 50 years and over, parti-
cipated in Wave 1 of this study, which took place between
October 2009 and July 2011. The study design of TILDA
has been described in detail elsewhere.25 Health and life-
style data were captured in participants’ own homes using
computerized aided personal interview (CAPI).26 The pre-
sence or absence of eye pathology was determined using
the CAPI with the question ‘’has a doctor ever told you if
you had any of the following conditions: diabetes, AMD,
cataracts or glaucoma’’. Participants were also asked
whether they had ever been told by a doctor if they had
high cholesterol or high blood pressure. Participants were
asked to record all medications that they took on
a regular basis, including those related to diabetes, such
as oral hypoglycaemic agents (OHAs) and/or insulin,
which were coded using the Anatomic Therapeutic
Classification (ATC) system. Participants were asked if
they currently smoked or had ever smoked cigarettes
regularly (daily for at least a year), and were categorized
as never smoked, past smokers or current smokers. The
International Physical Activity Questionnaire (IPAQ) was
used to classify participants’ level of physical activity into
low, moderate or high levels. All participants were invited
to attend a health assessment in one of two locations,
Dublin or Cork. Macular pigment measurement was
only conducted on participants who attended a health
center, therefore, a number of participants were automa-
tically excluded from the current analysis: i.e. if they were
unable to travel to a health center or opted for a home
assessment instead (n = 881) and/or refrained from hav-
ing either a home or health assessment (n = 2,267).
A total of 5027 individuals participated in a health assess-
ment, carried out by trained research nurses (Figure 1).
This research adhered to the tenets of the Declaration of
Helsinki and was approved by the Technological
University Dublin Research Ethics Committee. All parti-
cipants provided written informed consent prior to parti-
cipation in the study.
Diabetes classification
Diabetes type was classified into ‘no diabetes’, ‘pre-
diabetes’, ‘diagnosed diabetes’ and ‘undiagnosed diabetes’.
Diagnosed diabetes was identified from the CAPI with the
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question ‘has a doctor ever told you that you have dia-
betes or high blood sugar?’ and also from prescribed
diabetes medications at the time of the interview, identi-
fied using the ATC codes ‘A10A’ for insulin and ‘A10B’
for oral hypoglycemic medications. A blood sample was
provided for serum analysis. Glycated haemoglobin
(HbA1c), a long-term indicator of glycaemic control,
was measured and participants were further classified as
having ‘pre-diabetes,’ and ‘undiagnosed diabetes’ against
American Diabetes Association cut-off values.27 The
TILDA protocol for blood sample collection, processing
and storage has been described previously.26 Eleven
respondents who reported a doctors diagnosis of diabetes
before the age of 40 and who were on insulin therapy at
the time of interview were excluded from analysis due to
the suspicion that they might have Type 1 diabetes, in
line with previously published data,28 (Figure 1). Duration
of disease was quantified by asking those with a previous
diagnosis ‘how old they were when first diagnosed?’
Macular pigment optical density assessment
Corrected visual acuity was measured in both eyes using the
Early Treatment Diabetic Retinopathy Study (ETDRS)
LogMAR chart at a distance of 4 metres, using the partici-
pants existing prescription where necessary. The eye with the
best visual acuity was chosen for the MP assessment or if
there was equal vision in both eyes, the right eye was chosen.
MPOD was measured by customized heterochromatic flicker
photometry (c-HFP) centrally at 0.5° of retinal eccentricity
using the Macular Metrics Densitometer (Macular Metrics,
Rehoboth, MA). The established method employed for mea-
suring MP has been described in detail previously.29 Of the
5,027 participants who attended a health assessment, 2,904
Figure 1. Population included in analysis.
Abbreviations: AMD, age-related macular degeneration; MPOD, macular pigment optical density, n, number of participants; TILDA, The Irish Longitudinal Study on
Ageing; VA, Visual Acuity.
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were able to successfully complete MPOD assessment (parti-
cipants with diabetes, n = 310; non-diabetic controls,
n = 2,594). A number of subjects were excluded from the
overall MPOD analysis (n = 2,123) and possible reasons for
this included: poor fixation, technical issues, poor visual
acuity (visual acuity 6/18 Snellen (≤ 0.5 LogMAR)) and retinal
pathology (AMD, glaucoma). Because Type 1 and 2 diabetes
are considered different clinical conditions, the presenting
features of the condition (adiposity, dyslipidaemia, oxidative
stress and inflammation) may not be uniform across both and
may have different relationships with MPOD, therefore,
a number of participants with suspect Type 1 diabetes
(n = 11), were excluded from the current study. Participants
with pre-diabetes (HbA1c: 5.7–6.4%) were also excluded from
the current analysis (n = 122). Of the 8,500 participants that
took part in Wave 1 of TILDA, 188 Type 2 diabetes partici-
pants and 2,594 controls were deemed suitable for the study
(Figure 1).
Anthropometric assessment
Height (cm) and weight (kg) were measured to one decimal
place as described in detail elsewhere.26 Body mass index
(BMI) was calculated from measured height and weight as:
weight (kg)/height (m2). Waist circumference (WC) and hip
were measured to the nearest cm. Waist-to-height ratio
(WHtR) and waist-to-hip ratio (WHpR) were calculated
based on these measured data. Cut-offs were applied to clas-
sify participants as obese or non-obese for the following vari-
ables (BMI; WC; WHtR and WHpR).30
Blood pressure
Two blood pressure (BP) measurements were taken using the
OMRONTM digital automatic blood pressure monitor (Model
M10-IT) with arm cuff.26 Seated mean systolic (mmHg) and
mean diastolic (mmHg) BPwere used for analysis. The participant
was defined as hypertensive if mean seated systolic BP exceeded
140 mmHg or mean seated diastolic BP exceeded 90 mmHg.
Serum analysis
Respondents were not asked to fast before the health assessment.
Blood was extracted using defined phlebotomy protocols,26 and
analyzed for a complete lipid profile, which included total choles-
terol (TC), high density lipoprotein (HDL), low density lipopro-
tein (LDL) and triglycerides (TG), measured in millimoles per
litre (mmol/L). TG to HDL ratio, TC to HDL ratio and non-HDL
cholesterol (TC minus HDL) were calculated for subsequent
analyses. Cut-offs were applied to indicate high or ideal serum
lipid levels as per 2016 European Society of Cardiology (ESC)/
European Atherosclerosis Society (EAS) guidelines.31 Research
suggests that inflammation plays a role in the development of
Type 2 diabetes,32,33 therefore, anti-inflammatory marker serum
vitamin D [(25(OH)D); nanomoles per litre (nmol/L)] and
inflammatory marker C reactive protein (CRP), [micrograms
per litre (mg/L)] were also measured. Respondents were consid-
ered vitamin D deficient if serum levels were ≤ 50 nmol/L, and
sufficient if serum levels were >50 nmol/L as per the Institute of
Medicine (IOM) vitamin D guidelines.34 A threshold of >3.00mg/
L for high and ≤ 3.00mg/L as ideal was used for serum CRP.35
Statistical analysis
The statistical software package SPSS for Microsoft Windows
(version 23.0; IBM Corp., Armonk, NY) was used for all
analyses. To account for the fact that the study response rate
varied among different subgroups of the population, inverse
probability weights were calculated for the main sample using
the Quarterly National Household Survey (2010).36
Participation rates for the health centre assessment also varied
according to geographic location, health, education, age and
smoking, therefore a specific “health centre weighting” was
applied. A more detailed description of the weighting proce-
dure used in TILDA is described by Barrett et al.36
Our data are presented as mean ± standard deviation
throughout. These data were tested for normality using the
Kolmogorov-Smirnov test. For group comparison between par-
ticipants with diabetes and non-diabetic controls, one-way
analysis of variance (ANOVA) was used to test for differences
in means for normally distributed parameters, while the
Kruskal-Wallis test was used to test differences between
group medians for non-normally distributed parameters. For
categorical data, cross-tabulation with Chi-square analysis was
used. The distribution of MPOD was skewed, therefore,
a square root transformation of the MPOD data was per-
formed. The derived data were normally distributed and used
as the dependent variable for subsequent statistical analyses of
MPOD on the diabetes group. For ease of interpretation, mean
and SD of MPOD data is presented as the non-transformed
original measure for Type 2 diabetes participants. Pearson’s
product-moment correlation tests were performed to assess
the relationship between normalized MPOD and other study
variables where appropriate. Boxplots and scatterplots were
used to graphically highlight statistical findings. Multiple linear
regression was used to investigate the un-confounded associa-
tions between behavioral, anthropometric, clinical and serum
biomarker indicators and normalized MPOD. The level of
statistical significance was set at p < .05 for all analyses.
Results
Two thousand seven hundred and eighty two subjects, ana-
lyzed as part of Wave 1 of TILDA, were divided into two
study groups: Group 1: Normal controls (n = 2,594) and
Group 2: Type 2 diabetes (n = 188). Respondents ‘diagnosed
with diabetes’ and those with ‘undiagnosed diabetes’ were
grouped together and classified as having Type 2 diabetes
for subsequent analyses. Characteristics of the study popula-
tion according to their diabetes status are presented in Table
1. Group average MPOD was 10.3% lower in participants with
Type 2 diabetes [mean MPOD = 0.20(0.148)] compared with
non-diabetic controls [mean MPOD = 0.223(0.161)], and this
difference was statistically significant [t (2780) = −1.989,
p = .047)]. Participants with Type 2 diabetes also differed
from the control group across all other demographic, beha-
vioral, anthropometric, clinical and serum parameters exam-
ined (p < .0001 for all), with the exception of education
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(primary, secondary or third level), alcohol intake, and serum
TC to HDL ratio (p > .05 for these variables; Table 1).
Participants with diabetes were older, and more likely to be
male with a current or past history of tobacco use. In general
terms, the behavioral, clinical and anthropometric profile of
these participants was poorer than that observed in the con-
trol group, with lower levels of physical activity, greater levels
of obesity and higher prevalence of hypertension and cataract.
Similarly, serum analysis revealed that participants with dia-
betes were typically more hyperglycemic, more dyslipidemic
and displayed greater anti-inflammatory marker elevation
(serum vitamin D) and inflammatory marker elevation
(CRP), than the control group.
Biomarker associations with MPOD among participants
with diabetes
Demographic and behavioral factors
Smoking was the only demographic or behavioral factor sig-
nificantly associated with lower MPOD (F (2,185) = 6.019,
p = .003). Post hoc analysis revealed that participants who
never smoked had significantly higher normalized MPOD
(mean = 0.235(0.148)) compared with current smokers
(mean = 0.124(0.113); t (96); = 3.58, p = .001). There was
also a significant difference in MPOD between past
(mean = 0.19[0.151] and current smokers (t (116); = 2.268,
p = .025). However, there was no significant difference in
Table 1. Characteristics of the Study Population according to Diabetic Status.
Normal Controls
(n = 2594)
Type 2 Diabetics
(n = 188) p
Demographic Factors
Age years (Mean (SD)) 61.40(7.62) 64.73(8.32) 0.0001*
Age category years † (%)
50–64 68.12% 51.06% 0.0001 ‡
65–74 24.94% 35.64%
>75 6.94% 13.30%
Sex (%)
Male 43.79% 64.89% 0.0001 ‡
Female 56.21% 35.11%
Education (%)
Primary 18.81% 22.34% 0.174 ‡
Secondary 41.60% 44.68%
Third level 39.59% 32.98%
Behavioral Factors
Smoking (%)
Current 13.42% 14.89% 0.027 ‡
Past 39.36% 47.87%
Never 47.22% 37.23%
Alcohol (%)
Yes 78.83% 72.87% 0.130 ‡
No 18.47% 22.87%
NA 6.51% 3.72%
Exercise (%)
Low 37.90% 54.25% 0.0001 ‡
Moderate 30.07% 28.19%
High 32.03% 17.55%
Anthropometric & Clinical Biomarkers (Mean (SD))
BMI, kg/m2 27.98 (4.42) 32.32 (6.25) 0.0001*
WC, cm 93.19 (12.83) 105.47 (13.74) 0.0001*
WHtR 0.56 (0.070) 0.63 (0.08) 0.0001*
WHpR 0.894 (0.083) 0.96 (0.08) 0.0001*
Hypertensive (untreated) 5.82% 2.66% 0.0001‡
Hypertensive (treated) 24.79% 52.19%
Normotensive 69.39% 44.15%
MPOD** (Mean (SD)) 0.223(0.161) 0.20(0.148) 0.047††
Cataracts (%) 6.51% 13.83% 0.0001 ‡
Serum Biomarkers (Mean (SD))
TC mmol/L 5.24(1.04) 4.27(106) 0.0001*
HDL mmol/L 1.59(0.44) 1.27(0.33) 0.0001*
LDL mmol/L 3.01(0.92) 2.24(0.89) 0.0001*
TG mmol/L 1.66(1.03) 1.94(1.11) 0.0001*
TC/HDL Ratio 3.46(0.91) 3.473(0.92) 0.676*
TG/HDL Ratio 1.19(0.961) 1.68(1.12) 0.0001*
Non-HDL (TC-HDL) Ratio 3.65(0.946) 2.99(0.950 0.0001*
Vitamin D nmol/L 59.91(25.86) 51.90(22.72) 0.0001*
CRP mg/L 2.83(6.95) 5.23(11.94) 0.0001*
HbA1c % 5.06(0.27) 6.22(0.934) 0.0001*
‡ Chi-square test; *Kruskal–Wallis test; ††One-way analysis of variance (ANOVA);
MPOD sqrt; P values reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.
†Age: the age division corresponds to groupings used in previously published cohort studies.38
**MPOD, P values are reported using MPOD square root transformation (sqrt).
Abbreviations: BMI-body mass index; kg/m2- kilograms per metre squared; NA – non-applicable; WC-waist circumference; cm – centimetres; WHtR-waist-to-height ratio;
WHpR-waist-to-hip ratio. HbA1c-glycated hemoglobin; TC-Total cholesterol; HDL-High density lipoprotein; LDL-Low density lipoprotein; TG-Triglycerides; Non HDL- Total
cholesterol minus HDL; CRP-C-reactive protein; mmHg- millimetres of mercury; mmol/L -millimoles per litre; nmol/L -nanomols per litre; mg/L-micrograms per litre.
Normotensive (≤140 mmHg systolic; ≤90 mmHg diastolic); Hypertensive (>140 mmHg systolic; >90 mmHg diastolic).
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MPOD between non-smokers and past smokers (t
(158) = 1.723, p = .087); (Figure 2a).
Anthropometric and clinical biomarkers
MPOD was negatively correlated with BMI, WC and WHtR
(Pearson’s correlation = −0.202, −0.161, −0.189 respectively,
p < .05 for all), but not with WHpR (Pearson’s r = −0.111,
p > .05). Cut-offs were applied to classify participants as obese
and non-obese for all anthropometric measures, including BMI,
WC,WHtR andWHpR.30 MPOD, however, was not significantly
different in individuals with excess compared with normal adip-
osity indices for all anthropometric measures (p > .05 for all;
Table 2). Although MPOD tended to be lower in subjects with
cataracts, and in those with elevatedWHtR andWHpR (all trend-
ing towards significance), only hypertension emerged in the uni-
variate linear regression analysis as associated with lower MPOD
(Table 2; Figure 2b).
Serum biomarkers
MPOD was significantly lower among participants with
a raised TG to HDL ratio [Mean = 0.172 (0.140)] compared
to those with ideal levels (Mean = 0.215(0.152);
t (185); = 2.080, p = .039; Table 3; Figure 2c). ANOVA
revealed no significant difference in MPOD between those
with high and low TC, HDL, LDL, triglycerides, non-HDL
and TC/HDL (p = .287–0.946) (see Table 3). Participants who
were vitamin D deficient had significantly lower MPOD
[mean = 0.173(0.148)] compared to participants who had
sufficient levels [mean = 0.226 (0.145); t (185), = −2.796,
p = .006; Table 3; Figure 2d]. Figure 3 shows a significant
positive relationship between normalized MPOD and serum
vitamin D (r = 0.218, p = .003). There was no significant
association between MPOD and serum CRP levels (Table 3).
Multivariate model
Demographic and behavioural factors
Smoking remained a strong, negative predictor of MPOD
after adjusting for covariates. Current smoking was sig-
nificantly associated with lower MPOD (Beta co effi-
cient = – 0.097; p = .022; Table 4).
Anthropometric and physical biomarkers
The presence of cataract remained the only clinical parameter
to be negatively associated with MPOD in a diabetic popula-
tion after adjusting for covariates (Beta co efficient = – 0.078;
p < .049). None of the other anthropometric or clinical para-
meters (WHtR, hypertension, diabetic retinopathy or duration
of disease) remained significantly associated with MPOD in
this model (p > .05 for all).
Serum biomarkers
Vitamin D remained a significant and positive predictor of
MPOD in the multivariate model, although this was a subtle
effect (Beta co efficient = 0.001; p = .029). None of the other
serum biomarkers (TG/HDL, HbA1c or CRP) remained sig-
nificantly associated with MPOD (p > .05 for these variables).
The correlates of MPOD identified as significant in the
multivariate regression model (smoking, cataracts and low
vitamin D status) contributed 18.5% of the overall variability
in MPOD status amongst patients with Type 2 diabetes, (F
(13,146) = 2.545, p = .003; R2 = 0.185).
a
c
b
d
Figure 2. Box plots of MPOD by (a) Smoking status (b) Hypertension status (c) Triglyceride over High Density Lipoprotein ratio (d) Vitamin D 25(OH) D serum levels.
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Discussion
Consistent with previous investigations,17,18 this study pro-
vides further evidence that patients with Type 2 diabetes have
significantly lower MPOD, compared with non-diabetic con-
trols. Additionally, MPOD was inversely associated with
a range of behavioral, clinical and anthropometric biomarkers
including smoking, hypertension and bodyweight. Body mass
index, WHtR and WC were all negatively associated with
MPOD on univariate analysis, in the Type 2 diabetes group,
(Pearson’s r, p < .05 for all). Some novel relationships were
observed among the serum biomarkers, with low serum vita-
min D and raised TG/HDL ratio associated with low MPOD
levels; findings not previously reported. Current smoking, the
presence of cataract and low serum vitamin D persisted as
predictors of low MPOD in the multivariate model, after
adjusting for all other covariates, albeit collectively explaining
just 18.5% of the variability in MPOD.
Our finding that hypertensive participants with diabetes had
significantly lower MPOD compared to normotensive partici-
pants with diabetes is important given that hypertension is an
established risk factor for the development and progression of
DR.37 The association between MP and hypertension is not
well documented; however, one study has reported a link
between lower MPOD and a self-reported diagnosis of high
blood pressure.38 Chronic hypertension causes vascular
endothelial shear stress and circumferential wall stress.39 This,
in turn, leads to endothelial damage, increased ROS production
and activation of inflammatory cascades.40 One recent study
found lower levels of glutathione (GSH) and increased levels of
8-iso-prostaglandin 2α (8-iso-PGF2α), a marker of oxidative
stress, in diabetes patients with hypertension, supporting the
hypothesis that oxidative stress increases considerably in
hypertension, especially as a diabetic co-morbidity.41
Endogenous antioxidants become depleted when both condi-
tions coexist, which leads to an increased need for exogenous
antioxidants (i.e. vitamins C and E, carotenoids lutein, zeax-
anthin & meso-zeaxanthin) to balance redox status, which may
explain our observation that hypertension in the presence of
Type 2 diabetes may have an added negative impact on MPOD
status on univariate analysis. While we did not reach statistical
significance in multivariate analyses, future studies with larger
cohorts could further investigate this finding.
The inverse relationship observed between adiposity and
MPOD confirms previous findings among patients with Type
2 diabetes.18 Adipose tissue, visceral fat in particular; may act
as a sink/reservoir for macular carotenoids,23 thereby influen-
cing carotenoid concentrations in serum42 and subsequent
retinal uptake.24 Distribution of body fat is also a significant
factor, as it has been shown that concentrations of lutein and
zeaxanthin are higher in abdominal fat,43 and abdominal
adiposity is characteristic in Type 2 diabetes. Excess visceral
fat also contributes to inflammation and oxidative stress due
to the increased production of adipo-cytokines (Interleukin-1
(IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), tumor
necrosis factor alpha (TNF-alpha)).7 The chronic low grade
inflammation, associated with obesity and Type 2 diabetes
leads to increased oxidative stress and further inflammation,
putting a greater demand on antioxidant defences.
Antioxidant defences may also be lower in overweight/Type
2 diabetic patients, due to their lower intake of antioxidant
rich foods (e.g. fruits and vegetables), their increased utilisa-
tion of these molecules (e.g. increased inflammation/ROS in
insulin dependent tissue such as the retina) and their
impaired generation of other supportive anti-oxidants,
reviewed by Savini et al,44 which may collectively lead to
Table 2. MPOD according to Anthropometric and Clinical Biomarkers in a Diabetic Population (normalized MPOD).
n
188
Mean (SD)
MPOD 25th 50th 75th
sig
p
Anthropometric & Clinical Biomarkers
BMI (kg/m2)
Ideal (≤30) 122 0.200 (0.148) 0.087 0.177 0.304 0.964††
Excess (>30) 66 0.199 (0.150) 0.075 0.180 0.262
WC (cm)
Ideal (≤102 M, ≤88 F) 55 0.224 (0.140) 0.110 0.208 0.337 0.101††
Excess (>102 M, >88 F) 132 0.191 (0.151) 0.076 0.162 0.264
WHpR
Ideal (≤1.00 M, ≤0.85 F) 84 0.222 (0.153) 0.090 0.210 0.305 0.075††
Excess (>1.00 M, >0.85 F) 103 0.183 (0.142) 0.072 0.138 0.259
WHtR
Ideal (≤0.57 M, ≤0.53 F) 45 0.237 (0.164) 0.088 0.228 0.379 0.073††
Excess (>0.57 M, >0.53 F) 142 0.189 (0.142) 0.086 0.172 0.267
Blood Pressure (mmHg)
Normotensive (≤140/90) 83 0.228 (0.166) 0.090 0.210 0.324 0.043††
Hypertensive (>140/90) 105 0.177 (0.130) 0.075 0.138 0.259
Diabetic Retinopathy
Yes 10 0.151 (0.134) 0.047 0.091 0.231 0.256††
No 152 0.204 (0.149) 0.088 0.180 0.296
Cataracts
Yes 26 0.150 (0.108) 0.087 0.180 0.304 0.068††
No 161 0.206 (0.153) 0.054 0.118 0.231
†† ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. P values are reported using MPOD square root transformation
(sqrt) (normalized MPOD) and reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.
The following cut-offs were applied to indicate ideal or excess obesity measures and normotensive/hypertension for the following variables: BMI-body mass index; [ideal ≤
30; excess > 30 kg/m2 – kilograms per metre squared; WC-waist circumference; ideal ≤ 88 F; ≤ 102 M; excess > 88 F; >102 M cm – centimetres; WHtR-waist-to-height ratio;
ideal ≤ 0.53 F; ≤ 0.57 M; excess >0.57 F; >0.53 M; WHpR-waist-to-hip ratio; ideal ≤ 0.85 F; ≤1.00 M; excess > 0.85 F; >1.00 M; M = Male; F = Female;30 Normotensive
(≤140 mmHg systolic; ≤90 mmHg diastolic); Hypertensive (>140 mmHg systolic; >90 mmHg diastolic).
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MPOD depletion.45 Dietary intake of lutein and zeaxanthin
was not, however, assessed as part of the TILDA study (this
limitation is discussed further below).
Of interest, and to our knowledge a novel finding; is that
MPOD was significantly lower for participants with a raised
TG to HDL ratio. This observation is important given that
Type 2 diabetes patients commonly display an altered
lipoprotein profile, termed diabetic dyslipidemia (i.e. raised
TGs and low HDL), and that diabetes patients in the current
study had indeed significantly higher TGs and significantly
lower HDL serum lipid levels than the non-diabetic control
group. The characteristic lipid profile of individuals with Type
2 diabetes46 may have important implications for MP levels in
the eye, as dietary carotenoids are transported on circulating
Table 3. MPOD according to Serum Biomarkers in a Diabetic Population (normalized MPOD).
n
188
Mean (SD)
MPOD 25th 50th 75th
sig
p
Serum Biomarkers
TC (mmol/L)
Ideal ≤ 5.00 141 0.207 (0.152) 0.088 0.182 0.304 0.287††
High >5.00 46 0.177 (0.138) 0.068 0.163 0.260
HDL (mmol/L)
Ideal >1.6 27 0.203 (0.138) 0.089 0.184 0.275 0.785††
Low ≤ 1.6 160 0.199 (0.1510 0.085 0.173 0.296
LDL (mmol/L)
Ideal ≤ 2.6 127 0.20 (0.147) 0.076 0.179 0.297 0.946††
High >2.6 10 0.199 (0.154) 0.087 0.0174 0.276
TG (mmol/L)
Ideal ≤ 1.7 97 0.203 (0.147) 0.099 0.177 0.285 0.491††
High >1.7 90 0.195 (0.151) 0.069 0.179 0.301
Non HDL (mmol/L)
Ideal ≤ 3.4 132 0.202 (0.146) 0.088 0.178 0.303 0.671††
High >3.4 55 0.194 (0.157) 0.072 0.172 0.263
TG/HDL C Ratio
Ideal ≤ 1.74 118 0.215 (0.152) 0.100 0.181 0.314 0.039††
High >1.74 69 0.172 (0.140) 0.053 0.119 0.248
Vitamin D (nmol/L)
Deficient ≤ 50 96 0.173 (0.148) 0.056 0.181 0.234 0.006††
Sufficient >50 91 0.226 (0.145) 0.103 0.209 0.336
CRP (mg/L)
Ideal ≤ 3.0 113 0.213 (0.158) 0.088 0.181 0.298 0.120††
High >3.0 74 0.178 (0.130) 0.069 0.167 0.262
HbA1c (%)
≤ 6.0 77 0.203 (0.160) 0.081 0.173 0.295 0.728††
> 6.0 97 0.190 (0.139) 0.081 0.177 0.259
††ANOVA was used to check for MPOD differences among serum biomarkers. P values are reported using MPOD square root transformation (sqrt)
(normalized MPOD) and reflect the probability associated with the given F statistic. Data is weighted. Sig., significance.
The following cut-offs were applied to serum levels: HDL, high density lipoprotein; [high risk ≤1.6; low risk >1.6 millimoles per litre (mmol/L)]; LDL, low
density lipoprotein; [high risk > 2.6; low risk ≤ 2.6 mmol/L]; TC, total cholesterol; [high risk > 5.00; low risk ≤ 5.00 mmol/L]; TG, triglycerides; [high risk
>1.7; low risk ≤1.7 mmol/L];TG/HDL, triglyceride to high density lipoprotein ratio; [high risk >1.74; low risk ≤1.74 mmol/L]; TC/HDL, total cholesterol to
high density lipoprotein ratio; [high risk >3.5; low risk ≤3.5 mmol/L]; Non-HDL, total cholesterol minus high density lipoprotein; [high risk >3.4; low risk ≤
3.4 mmol/L] as per 2016 ESC/EAS guidelines31; serum vitamin D (25(OH) D) levels in nanomoles per litre (nmol/L) [deficient ≤50; sufficient >50 nmol/L] as
per IOM vitamin D guidelines34; serum CRP levels in micrograms per litre (mg/L) [high > 3.00 mg/L; ideal ≤3.00 mg/L]35; and HbA1c (glycated
hemoglobin) in millimoles per mol (mmol/mol) [high > 6.00%; ideal ≤ 6.00% (42.1 mmol/mol) as per American Diabetes Association guidelines.27
Figure 3. Scatterplot showing a significant positive relationship between normalized MPOD and Vitamin D (25(OH) D) serum levels.
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lipoproteins.24 The general consensus is that xanthophylls
associate with HDL,47 and that HDL levels are therefore
important for the efficient delivery and uptake of lutein and
zeaxanthin to the eye.24 The relationship between MPOD and
serum lipid levels has previously been investigated in patients
with diabetes, with a marginal negative association between
MPOD and TGs and a marginal positive association between
MPOD and HDL observed (p < .08 for both).17 We previously
reported significantly lower levels of MPOD in patients with
Type 2 versus Type 1 diabetes, and noted significantly lower
HDL values within the Type 2 diabetes group, postulating that
lower HDL levels may have mediated this difference.18 More
recently, the DiVFuSS study,19 has demonstrated significant
improvements in serum LDL, HDL and TGs, in a group of
patients with diabetes who participated in a 6-month rando-
mized control trial (RCT). The coincident increase in MPOD
observed in the intervention group may have been partially
mediated by these favourable changes in lipid profile.24 We
acknowledge, however, that the lack of dietary information on
carotenoid intake is a limitation of the current study, (dis-
cussed in further detail below), as MPOD is influenced by
both lutein and zeaxanthin intake as well as transport and
assimilation (i.e. mediated by HDL) in the target tissue. This
information would have added to the interpretation of our
findings. While we found that lower MPOD was associated
with raised serum TG/HDL levels on univariate analysis
(p = .039), serum TG/HDL did not remain as a predictor of
MPOD in multivariate analyses. Future studies, however,
based on a larger number of diabetic participants could
further investigate this finding.
Our findings in relation to smoking are not surprising
given that smoking is associated with increased oxidative
stress, not only through the increased systemic production
of ROS, but also through weakening of the antioxidant
defence systems.48 The reported associations between
cigarette smoking and DR, however, are more variable, with
some studies reporting an association,49 while others have
found no such relationship.50 Chronic hyperglycemia causes
oxidative stress, so the increased production of ROS in dia-
betes may be compounded further by smoking, another
important source of free radicals. Exposure to cigarette smok-
ing causes profound oxidative damage to human retinal pig-
ment epithelium (RPE) cells.51 Interestingly, we found no
difference in MPOD between previous smokers and non-
smokers, perhaps indicating that MPOD repletion is possible
in diabetes patients through smoking cessation.
Cataract status remained a predictor of low MPOD in the
multivariate model in line with previous observations.52,53
The marginal statistical significance of this association in the
univariate model (p = .068) was more than likely limited by
the small sample size in the current study (n = 26 with
cataracts). The evidence that carotenoids, lutein and zeax-
anthin, are protective against the development of cataract,
however, is well documented,52,53 suggesting the possibility
of a causal role for MPOD depletion in the pathogenesis of
cataract development in diabetes. With aging there is
a natural decrease in the production of antioxidants and
antioxidant enzymes, and a concomitant increase in photo-
toxic chromophores in the lens.54 Phototoxic reactions,
whether caused by endogenous or exogenous singlet oxygen
photosensitizers, lead to a modification of lens proteins, which
eventually causes opacification of the lens (i.e. cataractogen-
esis) (reviewed by Roberts & Dennison.)54 The phototoxic
reaction damage can be prevented by the appropriate antiox-
idant quenchers. Lutein and zeaxanthin both accumulate in
the lens55 and research has shown a lower prevalence of
nuclear cataract amongst those with higher intakes of
xanthophylls.53 Furthermore, findings from the age related
eye disease study (AREDS 2) revealed that participants in
the lowest quintile of dietary lutein/zeaxanthin intake experi-
enced slower cataract progression with carotenoid
supplementation.52 Although the development of cataract is
an age-related phenomenon, other factors appear to influence
their progression including poor diet, smoking, ultra violet
light exposure and metabolic factors. In the current study,
a greater percentage of patients with diabetes had cataract
(13.83%) compared with controls (6.51%), (p < .0001).
Cataract status does not appear to relate to MPOD levels
among non-diabetic individuals,38 suggesting a relationship
that is particular to cataract in the presence of Type 2 dia-
betes, which may impact MPOD levels in this patient group.
To our knowledge, this is the first study to report an associa-
tion between low MPOD and the presence of cataract in
diabetes.
That vitamin D emerged as a positive predictor of MPOD
in Type 2 diabetes after controlling for other covariates repre-
sents a particularly novel and interesting finding. Although
the best known function of vitamin D is to help the body
absorb and use calcium, other important roles include protec-
tion of the eye during inflammation, oxidative stress, fibrosis,
and angiogenesis.56 Vitamin D insufficiency is common
amongst the general population, and particularly amongst
those who are obese57 or who have diabetes.58 Our findings
support this observation as both the control and Type 2
Table 4. Multivariate Relationship between Behavioral, Anthropometric, Clinical,
Serum Biomarkers and MPOD in a Diabetic population (n = 188).
Independent Unstandardized MPOD sqrt
Variable Beta Coefficient Std Error T p
Constant 0.428 0.197 2.175 0.031
Age 0.001 0.002 0.700 0.485
Sex* (Female) −0.007 0.025 −0.259 0.796
Smoking†
Past −0.028 0.031 −0.913 0.363
Current −0.097 0.042 −2.316 0.022
WHtR −0.192 0.183 −1.046 0.297
Cataracts‡ (Yes) −0.078 0.039 −1.988 0.049
Vitamin D nmol/L 0.001 0.001 2.204 0.029
CRP mg/L 0.001 0.001 1.382 0.169
TG/HDL Ratio −0.015 0.013 −1.170 0.244
HbA1c % −0.006 0.017 −0.373 0.710
Duration (years) 0.003 0.003 1.093 0.276
Retinopathy†† (Yes) −0.092 0.058 1.585 0.115
Hypertension ‡‡ (No) 0.035 0.027 1.302 0.195
r2 = 0.185; F = 2.545; p = 0.003. Dependent variable = MPOD sqrt (normalized
MPOD); Data is weighted. Std. Error, Standard Error.
*Male = control group; † Never smoked = control group; ‡ No
Cataracts = control group; ††No Diabetic Retinopathy = Control group; ‡‡
Hypertension = Control group.
Abbreviations: CRP – C-reactive protein; HbA1c- glycated hemoglobin; mg/L –
micrograms per litre; nmol/L – nanomoles per litre; WHtR- waist to height
ratio; TG/HDL- triglyceride to high density lipoprotein ratio.
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diabetes group had mean vitamin D levels which fell well
below the optimal recommended level,59 and as the partici-
pants with Type 2 diabetes had significantly lower serum
vitamin D compared with the control group (p < .0001).
Vitamin D receptors (VDRs) are expressed in the eye, includ-
ing the RPE60 which suggests that vitamin D is biologically
relevant to the eye.61 Research shows that human adult RPE
cells (ARPE-19) also express the 1α-hydroxylase enzyme
required to convert 25(OH) D to its biologically active
1,25(OH)2 D form.
62
The ability to inhibit neovascularisation has also led
researchers to examine vitamin D’s involvement in DR
development.63 Serum vitamin D concentrations have pre-
viously been found to be inversely related to the severity of
retinopathy in patients with diabetes,61 with this study sug-
gesting that the measurement of serum 1,25(OH) 2 D3 con-
centrations might be helpful in predicting retinopathy
progression, and that a detailed ophthalmologic examination
is indicated for diabetes patients whose serum vitamin
D levels are low.61 The DiVFuSS study recently examined
the effects of supplementation with a novel multi-
component nutritional supplement, which included vitamin
D and the antioxidants lutein and zeaxanthin, on ocular
health and visual function in a group of participants with
diabetes.19 Individuals receiving the DiVFuSS formula
improved on all measures of visual function, and although
not statistically significant (p = .07), four subjects were down-
graded from moderate to mild non proliferative DR following
the intervention, while one subject on placebo was upgraded
from mild to moderate non proliferative DR over the same
period.19 Positive outcomes from DiVFuSS may in part be due
to supplementation with a compound that specifically targets
both inflammation and oxidative stress. It is plausible that
these findings may have been mediated by enhancements in
MPOD (27% mean increase in DiVFuSS group vs 2% mean
decrease in placebo group), and by vitamin D’s attenuating
effect on inflammation with reductions in serum high sensi-
tivity (hs)-CRP (60% mean decrease in DiVFuSS group vs
11% mean decrease in placebo group).19 Although CRP levels
were significantly higher in participants with diabetes
[mean = 5.23(11.94)], compared with non-diabetic controls
[mean = 2.83(6.95)], (p = .0001), in our study, MPOD was not
significantly different in diabetic participants with an elevated
CRP level compared with ideal levels (p = .120; Table 3).
These findings, however, warrant further investigation.
There are a number of important limitations to the current
study which should be recognized. Firstly, the use of self-
reported data is not ideal. Diabetes diagnosis was based on
respondent’s recall rather than health records. Concomitantly,
respondents were not explicitly asked what type of diabetes
they had. Instead patient medications (self-reported) and age
at diagnosis were used to account for possible Type 1 cases,
which may have led to some misclassification. The presence
or absence of cataract was also based on patient’s recall rather
than direct examination. Secondly, small patient numbers in
some of the sub-group analyses may have limited the statis-
tical power to detect associations that may exist (Type II error
possibility). It is worth noting that the prevalence of diag-
nosed and undiagnosed Type 2 diabetes in these older adults
resident in Ireland was found to be relatively low compared to
other populations (8.6% and 0.9% respectively), which would
account for low participant numbers in the current study.10,28
Another limitation was that dietary intake of the macular
carotenoids was also not assessed, therefore, it was not possi-
ble to control for potential confounding from variable intake
of lutein and zeaxanthin. Macular pigment constituent caro-
tenoids cannot be synthesised de novo in humans, therefore,
lower levels of MPOD may be experienced in participants
with poor dietary intake of antioxidants. Mares et al64 found
that MPOD was directly related to dietary intake of carote-
noids, lutein and zeaxanthin, but even more strongly with
serum levels, suggesting that unmeasured physical and med-
ical factors may also influence the uptake, distribution and
utilization of lutein and zeaxanthin.64 The absence of serum
analysis of lutein and zeaxanthin was also a weakness in our
study. Furthermore, it is worth noting that measures of MP
are subject to genetic variation. MPOD is a multi-factorial
phenotype, associated with variation in genes related to car-
otenoid transport, uptake and metabolism, and may be inde-
pendent of known dietary and health influences in MPOD.65
The MP determinants reported herein (current smoking, pre-
sence of cataracts and vitamin D status) explained 18.5% of
the overall variability in MPOD, in participants with diabetes.
Diet is an important determinant of MPOD, therefore, cau-
tionary interpretation of our findings is advised. Finally, while
the current study used a large, nationally representative popu-
lation, MPOD was only measured on participants who were
able to attend a health center.
Despite these drawbacks, there were a number of strengths
to the current analysis. The design of the TILDA study is
a particular strength, in particular the selection of participants
from which our diabetes and controls were drawn, which was
representative of the Irish population aged 50 and over.
Serum lipoproteins (HDL, TG/HDL) and inflammatory mar-
kers (vitamin D, CRP) were analyzed and blood pressure was
measured, which represents an advance on previous research
carried out, research which was based on self-reported doc-
tors’ diagnosis of high cholesterol and hypertension.38 The
additional use of HbA1c helped identify undiagnosed and
pre-diabetes cases. Finally, anthropometric measures such as
WtHtR and WHpR, were used to analyse overweight/obesity
in conjunction with BMI and WC.
Overall our findings suggest that individuals with Type 2
diabetes have lower MP relative to healthy controls, although
the clinical importance of the observed level of difference is
questionable. Future studies with larger cohorts could further
investigate this finding, as the difference in MPOD, although
significant (p = .047), was marginal. Hyperglycemia and other
anthropometric, metabolic and clinical correlates associated
with diabetes (e.g. excess adiposity, dyslipidemia, hyperten-
sion, and cataract), may relate to a state of chronic oxidative
stress and inflammation, processes which also underlie many
of the functional alterations in retinal vasculature in DR. Both
over utilization (i.e. in response to elevated oxidative stress/
inflammation) and under supply of antioxidant nutrients
(dietary deficiency, excess adiposity, and dyslipidemia) may
contribute to lower levels of MP in the diabetic retina. Clinical
benefits may be realised through the early identification of
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MPOD depletion in Type 2 diabetes. Given the borderline
statistical significance of many of our findings, more work
needs to be done to verify and refine our understanding of the
observed relationships. The MPOD difference of 0.053 OD in
participants with sufficient vitamin D (>50nmol/L) versus
deficient levels (≤50 nmol/L), although significant (p < .006),
is not clinically meaningful as it stands. MPOD measurement
is not routinely available, however, the capacity of commonly-
measured surrogate serum biomarkers (HDL, TG/HDL, vita-
min D), and anthropometric measurements (WHtR, WC) to
identify people with diabetes at risk of low MP merits further
consideration. The novel and important findings reported
herein should now be subject to further research, to better
understand the nature of any relationships that may exist.
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